RNTX Research | Milton Maxwell

RNTX

Rein Therapeutics Inc.

1.3500

-0.1300-8.78%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

35.49M

P/E (TTM)

Basic EPS (TTM)

-2.94

Dividend Yield

Recent Filings

8-K

Terminates Yorkville financing deals

12/11/25Dec 11, 2025

Rein Therapeutics terminated its Pre-Paid Advance Agreement and Standby Equity Purchase Agreement with Yorkville on December 11, 2025, after drawing $3 million under the PPA—latest on October 23—with zero SEPA sales. No penalties hit. Clean break frees the company from future dilution risks.

10-Q

Q3 FY2025 results

11/14/25Nov 14, 2025

Rein Therapeutics narrowed its Q3 operating loss to $5.5M from $6.1M y/y (derived), trimming R&D to $1.7M from $3.7M amid LTI-03's FDA clinical hold, now lifted October 29 for Phase 2 RENEW IPF trial resumption. Cash burn eased to $16.1M YTD from $17.5M y/y, with $4.0M cash at quarter-end funding into December 2025 via Yorkville pre-paid advances. G&A jumped to $3.8M from $2.3M y/y on stock-based comp and fees. EPS improved to -$0.21 from -$0.27, reconciling to 26.4M diluted shares. FDA hold resolved fast. Cash runway burns fast.

8-K

FDA clears LTI-03 trial resumption

11/3/25Nov 3, 2025

Rein Therapeutics secured FDA clearance on November 3, 2025, lifting the clinical hold on its U.S. Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis. Enrollment resumes late 2025 or early 2026 across 20 U.S. sites, complementing global efforts. Topline data due Q3 2026. FDA concerns fully resolved.

8-K

Third $1M advance drawn

10/24/25Oct 24, 2025

Rein Therapeutics secured a third $1.0 million pre-paid advance from Yorkville on October 23, 2025, netting $0.95 million under its July 2025 agreement allowing up to $6.0 million over 12 months. This equity-linked funding, with 8% interest and share offsets at market prices, bolsters liquidity while diluting shareholders through issuances like the prior 1.88 million shares. Repayment falls due in 12 months. Advances hinge on Yorkville's consent.

8-K

Second $1M advance drawn

9/9/25Sep 9, 2025

Rein Therapeutics secured a second $1.0 million Pre-Paid Advance from Yorkville on September 8, 2025, netting $0.95 million after a 5% discount, under the July 2025 agreement allowing up to $6.0 million over 12 months at 8% interest. This bolsters liquidity while enabling Yorkville to convert balances into common stock shares, as seen with 479,036 shares already issued against the initial advance at $1.06 average. Advances mature in 12 months. Dilution looms with ongoing equity offsets.

About

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.

CEO

Dr. James Brian Windsor Ph.D.

IPO

6/29/2017

Website

https://www.reintx.com

Employees

Sector

Healthcare

Industry

Biotechnology